Health Canada authorizes updated Novavax COVID-19 vaccine targeting XBB variant
OTTAWA — Health Canada authorized Novavax’s updated COVID-19 vaccine targeting the XBB.1.5 variant on Tuesday.
“Today’s expanded authorization will support the Canadian government’s strong commitment to provide its citizens with effective options, such as our protein-based non-mRNA vaccine, in the campaign against currently circulating COVID-19 variants,” said John C. Jacobs, president and CEO of Novavax in a news release issued Tuesday afternoon.
Nuvaxovid is a protein subunit vaccine, meaning it uses harmless pieces of the virus that causes COVID-19 to prime the immune system to fight it off.
The currently available XBB-targeting vaccines, manufactured by Pfizer-BioNTech and Moderna, both use messenger RNA (mRNA) technology to teach cells in the body how to make the virus’s spike protein and then generate an immune response against it.

